To the full analysis
CONMED stock: growth
CNMDCONMED reported $1.37B in revenue for fiscal 2025, up 5.2% on the prior year, up 9.8% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
4%
per year from 2006 to 2025, per share 3.4%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
6.9%
per year from 2006 to 2025, per share 6.3%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 9.8% | 6.7% | 4.0% |
| Revenue per share | 8.0% | 5.5% | 3.4% |
| Earnings | 37.7% | 4.4% | no data |
| Earnings per share | 35.7% | 3.3% | no data |
| Free cash flow | 24.0% | 16.4% | 6.9% |
| Free cash flow per share | 21.9% | 15.1% | 6.3% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $646.81M | −$12.51M | $42.68M |
| 2007 | $694.29M | $41.46M | $44.98M |
| 2008 | $742.18M | $44.56M | $25.27M |
| 2009 | $694.74M | $12.14M | $3.58M |
| 2010 | $713.72M | $30.35M | $23.51M |
| 2011 | $725.08M | $752K | $81.25M |
| 2012 | $767.14M | $40.48M | $73.67M |
| 2013 | $756.76M | $35.94M | $62.5M |
| 2014 | $734.47M | $32.19M | $49.77M |
| 2015 | $719.17M | $30.5M | $33.06M |
| 2016 | $763.52M | $14.66M | $23.47M |
| 2017 | $796.39M | $55.49M | $52.72M |
| 2018 | $859.63M | $40.85M | $58.19M |
| 2019 | $955.1M | $28.62M | $75.07M |
| 2020 | $862.46M | $9.52M | $51.52M |
| 2021 | $1.01B | $62.54M | $96.9M |
| 2022 | $1.05B | −$80.58M | $11.58M |
| 2023 | $1.24B | $64.46M | $106.32M |
| 2024 | $1.31B | $132.42M | $153.88M |
| 2025 | $1.37B | $47.06M | $150.88M |
Revenue by segment
How CONMED Corporation makes its money and how that has shifted. Names are as the company reports them.
- General Surgery58%
- Orthopedic Surgery42%
Figures as a table
| 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|
| General Surgery | $572.21M | $583.94M | $711.59M | $763.03M | $800.13M | 58.2% |
| Orthopedic Surgery | $438.42M | $461.53M | $533.16M | $543.99M | $574.6M | 41.8% |
| Total revenue | $1.01B | $1.05B | $1.24B | $1.31B | $1.37B | 100% |
Revenue by region
Where CONMED Corporation generates its revenue.
- United States56%
- EMEA19%
- Asia Pacific15%
- Americas (excluding the United States)9%
Figures as a table
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|
| United States | $482.06M | $552.53M | $578.95M | $700.16M | $748.22M | $774.59M | 56.4% |
| EMEA | $161.08M | $189.7M | $197.94M | $226.25M | $243.06M | $264.65M | 19.3% |
| Asia Pacific | $140.6M | $171.22M | $162.48M | $197.4M | $194.68M | $208.72M | 15.2% |
| Americas (excluding the United States) | $78.71M | $97.19M | $106.11M | $120.93M | $121.04M | $126.76M | 9.2% |
| Total revenue | $862.46M | $1.01B | $1.05B | $1.24B | $1.31B | $1.37B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 31 Mar 2024)
- Valuation signal Undervalued since 7 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.